SWI/SNF, Intellectual Disability and Tumor Development
======================================================

Heterozygous germline mutations in components of the SWI/SNF chromatin remodeling complexes have been identified in patients with syndromes that are associated with severe intellectual disability and speech delay. Because somatic and germline mutations in SWI/SNF components were previously implicated in tumor development, patients with intellectual disability caused by SWI/SNF mutations in the germline may be exposed to an increased risk of developing cancer. In this issue of *Epigenetics*, Santen et al. compared the mutational spectrum of SWI/SNF components in intellectual disability syndromes and cancer, discussing the implications for patients.

*BRCA1* Hypermethylation as Predictor of Sensitivity to Chemotherapy
====================================================================

Germline mutations in the *BRCA1* or *BRCA2* genes are associated with an increased risk of breast and ovarian cancer development. These two genes are involved in DNA repair, and tumors harboring genetic defects in them are thought to be more sensitive to DNA-damaging agents used in chemotherapy. In this issue of *Epigenetics*, Stefansson et al. show that, in cancer cell lines and xenografted tumors, *BRCA1* CpG island promoter hypermethylation-associated silencing can predict enhanced sensitivity to platinum-derived drugs to the same extent as *BRCA1* mutations. *BRCA1* hypermethylation appears to be a predictor of longer time to relapse and improved overall survival in ovarian cancer patients undergoing chemotherapy with cisplatin.

Aberrant DNA Methylation of miRNA Genes in HCC
==============================================

Downregulation of miRNAs is a common feature observed in solid tumors, including hepatocellular carcinoma (HCC). Shen et al. have now employed a genome-wide approach to test whether DNA methylation alterations in miRNA host genes cause deregulated miRNA expression in HCC. The authors measured expression levels of three miRNAs (miR-10a, miR-10b and miR-196b) in a subset of HCC tumor and non-tumor tissues and identified a total of 54 CpG sites from 27 host genes that significantly differed in DNA methylation levels between tumor and adjacent non-tumor tissues. Fifty-three of these sites were significantly hypermethylated in tumor tissues and 15 sites had more than 2-fold tumor/non-tumor changes. Of note, significant downregulation of miR-10a was observed in tumor compared with non-tumor tissues.

Agglomerative DNA methylation in toxicant-induced malignant transformation
==========================================================================

Epigenetic dysfunction is a known mechanism involved in toxicant-induced malignant transformation caused by environmental carcinogens such as arsenicals or cadmium. In addition to aberrant DNA methylation of single genes, another manifestation of epigenetic dysfunction in cancer is agglomerative DNA methylation, which can participate in long-range epigenetic silencing that targets many neighboring genes and has been shown to occur in several types of clinical cancers. Severson et al. used in vitro model systems of toxicant-induced malignant transformation and found hundreds of aberrant DNA methylation events, some of which occurring in an agglomerative fashion. Agglomerative DNA methylation changes induced by arsenicals appeared to be common and clinically relevant events, since they occurred in other human cancer cell lines and in models of malignant transformation, as well as in clinical cancer specimens.

A Biomarker Panel for Cholangiocarcinoma
========================================

The study by Andresen et al. aimed at identifying novel epigenetic biomarkers with the potential to improve the diagnostic accuracy of cholangiocarcinoma. The authors analyzed microarray data of cholangiocarcinoma cell lines treated with epigenetic drugs and their untreated counterparts and compared them with previously published gene expression profiles of primary tumors and with non-malignant controls. The genes *CDO1*, *DCLK1*, *SFRP1* and *ZSCAN18* displayed high methylation frequencies in primary tumors and were unmethylated in controls. At least one of these four biomarkers was positive in 87% of the tumor samples, with a specificity of 100%. This novel methylation-based biomarker panel showed high sensitivity and specificity for cholangiocarcinoma.

Analyzing Serum DNA in Breast Cancer
====================================

Because tumors are capable of shedding DNA into the blood stream, serum DNA may be used to measure the degree of methylation in specific cancer-related genes. Sturgeon et al. obtained serum DNA from women who were about to undergo a breast biopsy or mastectomy and compared the methylation status of a panel of 12 genes in different groups of women. The authors found relatively consistent variation in methylation patterns among groups, but these modest differences did not provide sufficient ability to distinguish between cases and controls in a clinical setting.

Identifying Biomarkers in High-Grade CIN
========================================

The identification of hypermethylated regions allowing discrimination between normal cervical epithelium and high-grade cervical intraepithelial neoplasia (CIN) may improve current cervical cancer population-based screening programs. Lendvai et al. studied the DNA methylome of high-grade CIN lesions to identify potential biomarkers for early diagnosis of cervical neoplasia. The authors compared DNA methylation profiles of epithelial cells derived from high-grade CIN lesions with normal cervical epithelium and identified hypermethylated differentially methylated regions (DMRs). After validation, two genes, *COL25A1* and *KATNAL2*, and the specific hypermethylated DMR patterns observed in high-grade CIN lesions, appear to be good candidate biomarkers for early detection.

Regulation of *TIMP3* in Prostate Cancer
========================================

*Tissue inhibitor of metalloproteinase-3* (*TIMP3*) is a tumor suppressor gene frequently downregulated in prostate cancer. In this issue of *Epigenetics*, Shinojima et al. examined the contribution of both CpG site promoter methylation and histone modifications on *TIMP3* downregulation. Their results indicate that histone modifications can contribute to *TIMP3* repression in the absence of promoter hypermethylation, and suggest that the combination of histone modifying agents could restore *TIMP3* expression in prostate tumors harboring aberrant histone modifications at the *TIMP3* promoter.

Stress and the Adult Rat
========================

The regulation of the levels of glucocorticoid receptor (GR) is an important stress adaptation mechanism. Witzmann et al. now investigated how the *Gr* 1~7~ transcript is regulated by analyzing *Gr* promoter 1~7~ methylation and *Gr* 1~7~ expression in adult rats exposed to either acute or chronic stress paradigms. The authors observed a strong negative correlation between the sum of promoter-wide methylation levels and *Gr* 1~7~ transcript levels, independent of the stressor. Methylation of individual sites did not, however, correlate with transcript levels, suggesting that promoter 1~7~ was directly regulated by promoter-wide DNA methylation. The authors found that, in addition to the known perinatal programming, the *Gr* 1~7~ promoter is epigenetically regulated by chronic stress in adulthood, and retains promoter-wide tissue-specific plasticity.

Genome-wide DNA Methylation and Secondhand Smoke
================================================

Aberrant DNA methylation occurs frequently in lung cancer, with exposure to secondhand smoke (SHS) being an established risk factor. Tommasi et al. have now investigated the causal role of SHS in the genesis of lung cancer. The authors constructed whole DNA methylome of mice exposed to SHS for a duration of 4 mo. Their studies revealed that all groups of SHS-exposed mice and controls share a similar pattern of DNA methylation. The absence of locus-specific gain of DNA methylation and global loss of DNA methylation in the lung of SHS-exposed mice within a timeframe that precedes neoplastic-lesion formation underscore the challenges of lung cancer biomarker development.

PGE2 and *IL-8* Derepression in Human Astrocytoma
=================================================

In astrocytoma cells, the expression of *IL-8* is upregulated by prostaglandin E2 (PGE2). Venza et al. have now investigated whether *IL-8* activation by PGE2 involves changes in DNA methylation and/or histone modifications in astrocytoma specimens, astrocytoma cell lines and normal astrocytic cells. The authors have elucidated an orchestrated mechanism triggered by PGE2 whereby concurrent association of site-specific demethylation and histone H3 hyperacetylation resulted in derepression of *IL-8* gene expression in human astrocytoma.

A Biomarker for Nascent Smokers
===============================

Epigenetic modifications to peripheral white blood cell DNA occur in response to a wide variety of exposures. Broad changes in DNA methylation, particularly at the *aryl hydrocarbon receptor repressor* (*AHRR*) locus, occur in samples from subjects with long histories of smoking. What is the response at *AHRR* when the levels of smoking are low? Philibert et al. have now examined the association of smoking to genome lymphocyte DNA methylation status in individuals with less than one half-pack a year of exposure. The authors found a stepwise effect of smoking on DNA methylation among youth with relative brief exposure histories at a CpG residue in *AHRR* that was identified in previous studies and at which the effects of smoking were significant, even in those subjects with less than one half-pack a year exposure. Therefore, *AHRR* demethylation in peripheral cells may serve as an early, sensitive biomarker for even low levels of exposure to tobacco smoke, providing a non-self-report alternative for nascent exposure to tobacco smoke.
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